突变的固酶3A 能防止高血压引起的心脏损伤
Maria Ercu1,2, Michael B Mücke1,2,3, Tamara Pallien1,2
1Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany (M.E., M.B.M., T.P., A.S., C.S., A.A., D.Y.S.-F., P.H.D., B.I.M.F., R.W.-G., M.G., C.M., K.Z., T.L., S.S., M.T., H.N., A.H., D.C.M., S.D., F.Q., E.P., R.L., S.K.F., D.N.M., T.B., S.B., N.H., M.B., E.K.).
Circulation
|October 19, 2022
概括
二酶3A (PDE3A) 的功能增益突变导致高血压,但保护心脏免受损伤. 这表明模仿PDE3A突变效应可能提供长期的心脏保护.
科学领域:
- 心血管科学
- 遗传学
- 分子生物学
背景情况:
- 基酶3A (PDE3A) 的功能增益突变会导致带有支臂动脉 (HTNB) 的高血压,从而导致中风.
- 矛盾的是,HTNB患者没有出现心脏缩或心力衰竭,这表明PDE3A突变在心脏中起着保护作用.
研究的目的:
- 调查PDE3A突变在心脏中的保护机制,尽管它们具有高血压效应.
- 探索模仿PDE3A突变效应的潜力,以长期保护心脏.
主要方法:
- 研究了新的HTNB患者和CRISPR-Cas9工程的老鼠模型.
- 使用遥测血压,心声学,微型CT,RNA测序和单细胞RNA测序.
- 通过Ca2+成像,FRET和生物化学测试确定和分析人类诱导的多能干细胞衍生的心肌细胞.
主要成果:
- 鉴定出一个新的PDE3A突变,与之前鉴定出的4个突变一起,所有这些突变都导致了酶过活.
- 尽管高血压,但HTNB老鼠模型和患者的左心室正常;突变心脏表现出改善的收缩性和适应性Ca2+循环.
- RNA测序显示突变体的mRNA表达发生变化,影响新陈代谢和蛋白质折叠.
结论:
- PDE3A突变提供了对高血压引起的心脏损伤的保护,与它们对血管的影响形成鲜明对比.
- 在心脏中模仿PDE3A突变效应提供了潜在的长期心脏保护,与短期PDE3A抑制疗法不同.
- 这些发现可能有助于开发新的治疗方法,以预防高血压相关的心脏损伤.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
231
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
231
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
37
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
487
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
487
01:23Antihypertensive Drugs: Vasodilators
619
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
619
01:29Heart Failure II: Pathophysiology
31
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31